Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (ACTRN12626001033336) titled 'A study evaluating SIR4156 together with semaglutide to reduce body fat in adults with obesity' on Aug. 21.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: Sironax Aus Pty Ltd
Condition:
Obesity
Obesity
Metabolic and Endocrine - Metabolic disorders
Intervention:
Participants in the intervention arm will receive SIR4156 oral tablets administered twice daily in combination with semaglutide administered as a once-weekly subcutaneous injection for 24 weeks. Participants will receive either 100 mg or 200 mg S...